NASDAQ:NTRA - Natera Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Natera Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $28.79 +3.33 (+13.08 %) (As of 03/30/2020 04:00 PM ET) Add Compare Today's Range$24.92Now: $28.79▼$29.1450-Day Range$17.27MA: $33.12▼$40.1752-Week Range$16.87Now: $28.79▼$41.80Volume1.53 million shsAverage Volume883,987 shsMarket Capitalization$2.25 billionP/E RatioN/ADividend YieldN/ABeta1.13 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Natera, Inc., a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora products of conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Evercord, a cord blood and cord tissue processing and storage service; and Signatera, a circulating tumor DNA technology that analyzes and tracks mutations to an individual's tumor. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners in the United States and internationally. Natera, Inc. has research collaborations with the Institut Jules Bordet and Fox Chase Cancer Center. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.Read More Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NTRA Previous Symbol CUSIPN/A CIK1604821 Webhttp://www.natera.com/ Phone650-249-9090Debt Debt-to-Equity Ratio0.36 Current Ratio2.91 Quick Ratio2.84Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$302.33 million Price / Sales7.45 Cash FlowN/A Price / Cash FlowN/A Book Value$3.59 per share Price / Book8.02Profitability EPS (Most Recent Fiscal Year)($1.99) Net Income$-124,830,000.00 Net Margins-41.30% Return on Equity-120.68% Return on Assets-34.64%Miscellaneous Employees1,039 Outstanding Shares78,252,000Market Cap$2.25 billion Next Earnings Date5/14/2020 (Estimated) OptionableOptionable Receive NTRA News and Ratings via Email Sign-up to receive the latest news and ratings for NTRA and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:NTRA Rates by TradingView Natera (NASDAQ:NTRA) Frequently Asked Questions How has Natera's stock been impacted by COVID-19 (Coronavirus)? Natera's stock was trading at $31.02 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NTRA shares have decreased by 7.2% and is now trading at $28.79. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Natera? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Natera. When is Natera's next earnings date? Natera is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Natera. How were Natera's earnings last quarter? Natera Inc (NASDAQ:NTRA) issued its earnings results on Wednesday, February, 26th. The medical research company reported ($0.44) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.60) by $0.16. The medical research company earned $83.20 million during the quarter, compared to analysts' expectations of $77.84 million. Natera had a negative return on equity of 120.68% and a negative net margin of 41.30%. View Natera's earnings history. What guidance has Natera issued on next quarter's earnings? Natera issued an update on its FY 2020 After-Hours earnings guidance on Wednesday, February, 26th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $335-350 million, compared to the consensus revenue estimate of $334.88 million. What price target have analysts set for NTRA? 6 analysts have issued 12-month price objectives for Natera's stock. Their forecasts range from $32.00 to $49.00. On average, they anticipate Natera's share price to reach $43.83 in the next year. This suggests a possible upside of 52.3% from the stock's current price. View analysts' price targets for Natera. What are Wall Street analysts saying about Natera stock? Here are some recent quotes from research analysts about Natera stock: 1. According to Zacks Investment Research, "Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. " (1/23/2020) 2. Canaccord Genuity analysts commented, "We recently had the privilege of hosting Natera CEO Steve Chapman and CFO a well-attended fireside chat at the 39th in Boston. We continue to view NTRA as an undervalued cancer company trading at the multiple of an NIPT company. NTRA remains one of our favorite stocks and is one of our top picks for 2019. We reiterate our BUY rating and $38 PT. Signatera may be a game-changer in recurrence monitoring and MRD." (9/11/2019) Has Natera been receiving favorable news coverage? News articles about NTRA stock have trended negative on Monday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Natera earned a news sentiment score of -2.4 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutNatera. Are investors shorting Natera? Natera saw a increase in short interest in March. As of March 13th, there was short interest totaling 4,148,000 shares, an increase of 18.9% from the February 27th total of 3,490,000 shares. Based on an average daily trading volume, of 985,900 shares, the days-to-cover ratio is presently 4.2 days. Approximately 8.8% of the shares of the stock are short sold. View Natera's Current Options Chain. Who are some of Natera's key competitors? Some companies that are related to Natera include Guardant Health (GH), ELEKTA AB/ADR (EKTAY), InVitae (NVTA), Veracyte (VCYT), CareDx (CDNA), Castle Biosciences (CSTL), RadNet (RDNT), Centogene (CNTG), Personalis (PSNL), Fulgent Genetics (FLGT), DermTech (DMTK), Enzo Biochem (ENZ), Anpac Bio-Medical Science (ANPC), Celcuity (CELC) and Psychemedics (PMD). What other stocks do shareholders of Natera own? Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Athabasca Oil (ATH), Chipotle Mexican Grill (CMG), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN). Who are Natera's key executives? Natera's management team includes the following people: Dr. Matthew Rabinowitz, Co-Founder & Exec. Chairman (Age 46)Mr. Steve Chapman, CEO, Pres & Director (Age 40)Mr. Michael Brophy, Chief Financial Officer (Age 39)Mr. Jonathan Sheena, Co-Founder, Chief Technology Officer & Director (Age 46)Mr. Robert A. Schueren, Chief Operating Officer (Age 57) When did Natera IPO? (NTRA) raised $101 million in an initial public offering (IPO) on Thursday, July 2nd 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers. What is Natera's stock symbol? Natera trades on the NASDAQ under the ticker symbol "NTRA." Who are Natera's major shareholders? Natera's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Fred Alger Management LLC (4.79%), FMR LLC (4.76%), Jennison Associates LLC (3.27%), State Street Corp (3.21%), Macquarie Group Ltd. (2.40%) and Macquarie Group Ltd. (2.43%). Company insiders that own Natera stock include Claremont Creek Partners Fund, John Steuart, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Robert Alan Schueren and Steven Leonard Chapman. View institutional ownership trends for Natera. Which major investors are selling Natera stock? NTRA stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Driehaus Capital Management LLC, UBS Group AG, Macquarie Group Ltd., Macquarie Group Ltd., PNC Financial Services Group Inc., AXA, and Bank of New York Mellon Corp. Company insiders that have sold Natera company stock in the last year include Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Robert Alan Schueren, and Steven Leonard Chapman. View insider buying and selling activity for Natera. Which major investors are buying Natera stock? NTRA stock was bought by a variety of institutional investors in the last quarter, including Bridger Management LLC, Norges Bank, State Street Corp, Lord Abbett & CO. LLC, Renaissance Technologies LLC, Columbus Circle Investors, Parkman Healthcare Partners LLC, and Madison Asset Management LLC. View insider buying and selling activity for Natera. How do I buy shares of Natera? Shares of NTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Natera's stock price today? One share of NTRA stock can currently be purchased for approximately $28.79. How big of a company is Natera? Natera has a market capitalization of $2.25 billion and generates $302.33 million in revenue each year. The medical research company earns $-124,830,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Natera employs 1,039 workers across the globe. View additional information about Natera. What is Natera's official website? The official website for Natera is http://www.natera.com/. How can I contact Natera? Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The medical research company can be reached via phone at 650-249-9090 or via email at [email protected] MarketBeat Community Rating for Natera (NASDAQ NTRA)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 346 (Vote Outperform)Underperform Votes: 309 (Vote Underperform)Total Votes: 655MarketBeat's community ratings are surveys of what our community members think about Natera and other stocks. Vote "Outperform" if you believe NTRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTRA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/30/2020 by MarketBeat.com StaffFeatured Article: Catch-Up Contributions
